LitAlert ~~

    • Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    • Preobrazhenskaya EV, Shleykina AU, Gorustovich OA, Martianov AS, Bizin IV, Anisimova EI, Sokolova TN, Chuinyshena SA, Kuligina ES, Togo AV, Belyaev AM, Ivantsov AO, Sokolenko AP, Imyanitov EN.
    • Int J Cancer. 2020 Sep 30. doi: 10.1002/ijc.33317. Epub ahead of print.
    • Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    • Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.
    • PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197.
    • Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    • Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT.
    • PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Cancers (Basel). 2020 Sep 29;12(10):E2809. doi: 10.3390/cancers12102809.
    • First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
    • Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NR, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS.
    • Cancer Discov. 2020 Sep 28. doi: 10.1158/2159-8290.CD-20-0868. Epub ahead of print.

    Press: Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest (Precision Oncology News)

    • PARP Inhibition as Frontline Therapy in Ovarian Cancer.
    • Moore KN, Pothuri B, Monk B, Coleman RL.
    • Clin Adv Hematol Oncol. 2020 Sep;18(8):550-556.